MediWound (NASDAQ:MDWD – Free Report) had its price objective trimmed by HC Wainwright from $28.00 to $25.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Separately, StockNews.com upgraded shares of MediWound to a “sell” rating in a research report on Monday, August 5th.
Check Out Our Latest Analysis on MDWD
MediWound Stock Up 3.3 %
Institutional Trading of MediWound
Several institutional investors have recently made changes to their positions in MDWD. MetLife Investment Management LLC bought a new position in MediWound in the 3rd quarter worth approximately $89,000. Rhumbline Advisers bought a new position in shares of MediWound during the second quarter worth $131,000. Barclays PLC grew its stake in MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in MediWound in the 3rd quarter valued at $212,000. Finally, Bank of New York Mellon Corp purchased a new stake in MediWound in the 2nd quarter worth $342,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.
MediWound Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Articles
- Five stocks we like better than MediWound
- What is the Dow Jones Industrial Average (DJIA)?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Calculate Options Profits
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What is a SEC Filing?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.